Meet the Fund Manager
Matt McNamara Board Director & CIOHorizon 3 Biotech
Meet the Manager
Get access to some of Australia’s leading fund managers who share their 3 favourite stocks, investment approach and insights on the market.
Each session includes:
- 3 favourite stock opportunities
- Market views for the year ahead
- Investment strategy and approaches
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.
Horizon 3 Biotech, is a biotech venture capital company seeking to capitalise on opportunities presented by emerging therapeutic and medical device companies, and the low level of investment competition in the segment. The company manages the Horizon 3 Biotech Fund, a wholesale unit trust targeting $100 million in funding and a gross return of 20% per annum using an approach that hits key inflection points faster while limiting downside and increasing the upside. Matt McNamara has more than 30 years in healthcare and medical sciences and more than 20 years’ experience as a venture capitalist. His business acumen and strong background in the life sciences sector make him one of the industry’s most credible investment voices.
Andrew Chapman Merchant Group
Andrew Chapman, managing director of Merchant Group, has more than 20 years’ finance industry experience and market-tested knowledge on active portfolio management and risk – enabling him to offer customised investment solutions with a direct and transparent investment approach.
Samuel Berridge Perennial Partners
Samuel Berridge, portfolio manager and resources analyst, has 15 years’ experience across the mining and finance industries. He specialises in mining, mining services, oil and gas, hard commodity and small industrial sectors. In 2011, Samuel’s stock selection skills won him StarMine’s top Australian Metals and Mining Analyst Award.
Dean Fergie Cyan Investment Management
This session we were joined by Dean Fergie, head of Cyan Investment Management. In the session, Dean outlined his inclination for investing in newer businesses for a competitive advantage, and why he’s looking at the smaller end of the market to identify excess returns.